Literature DB >> 2295796

Elevated natural killer cell responses in mice infected with recombinant vaccinia virus encoding murine IL-2.

G Karupiah1, B E Coupar, M E Andrew, D B Boyle, S M Phillips, A Müllbacher, R V Blanden, I A Ramshaw.   

Abstract

The role of cytotoxic T cells and NK cells in the recovery of immunodeficient, athymic, nude mice infected with a recombinant vaccinia virus (VV) encoding murine IL-2 was investigated. Kinetic studies with the IL-2-encoding recombinant (VV-HA-IL2) and control (VV-HA-TK) viruses excluded a role for cytotoxic T cells but suggested the possible involvement of NK cells. In athymic nude mice given VV-HA-IL2, NK activity was at least threefold higher than mice infected with VV-HA-TK and this activity persisted for at least 6 days after infection. The effectors mediating the NK-like activity were asialo-GM1+ (as-GM1+), Thy1.2+/-, CD4- and CD8-, the phenotype of conventional NK cells. Elevated NK activity coincided with the rapid clearance of VV-HA-IL2 from ovaries of infected normal CBA/H mice but not from ovaries of CBA beige mice which had no detectable NK activity in spleens or ovaries. The expression of IL-2 in recombinant VV infection probably induces a cascade of immunologic effects of which elevated NK activity is one. We speculate that the chemoattractant and NK activity augmenting effects of IL-2 may contribute to recovery from VV-infection.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295796

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  32 in total

1.  Granzyme A is critical for recovery of mice from infection with the natural cytopathic viral pathogen, ectromelia.

Authors:  A Müllbacher; K Ebnet; R V Blanden; R T Hla; T Stehle; C Museteanu; M M Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

2.  Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox.

Authors:  R J Jackson; A J Ramsay; C D Christensen; S Beaton; D F Hall; I A Ramshaw
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

3.  Granzyme A, a noncytolytic component of CD8(+) cell granules, restricts the spread of herpes simplex virus in the peripheral nervous systems of experimentally infected mice.

Authors:  R A Pereira; M M Simon; A Simmons
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  T-bet is required for protection against vaccinia virus infection.

Authors:  Masanori Matsui; Osamu Moriya; Takayuki Yoshimoto; Toshitaka Akatsuka
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

Review 5.  Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.

Authors:  B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

6.  Importance of interferons in recovery from mousepox.

Authors:  G Karupiah; T N Fredrickson; K L Holmes; L H Khairallah; R M Buller
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

7.  Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection.

Authors:  Jennifer Martinez; Xiaopei Huang; Yiping Yang
Journal:  PLoS Pathog       Date:  2010-03-12       Impact factor: 6.823

8.  Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model.

Authors:  M Sivanandham; S D Scoggin; N Tanaka; M K Wallack
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

9.  The interferon-inducible chemokines MuMig and Crg-2 exhibit antiviral activity In vivo.

Authors:  S Mahalingam; J M Farber; G Karupiah
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

10.  Effects of virally expressed interleukin-10 on vaccinia virus infection in mice.

Authors:  M G Kurilla; S Swaminathan; R M Welsh; E Kieff; R R Brutkiewicz
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.